Company: BLTE
Filing Date: 2025-01-27
Form Type: 424B7
Source: 0001104659-25-006367
Chunk: 38

Company: BELITE BIO, INC
Filing Date: 2025-01-27
Form: 424B7
Chunk 38
---
 establish and maintain collaborations or licensing agreements;

•

our ability to identify and integrate new product candidates, technologies and/or suitable acquisition targets;

•

our ability to effectively manage our growth;

•

changes to regulatory and operating conditions in our industry and markets; and

•

the potential impact of COVID-19 and other epidemics on our current and future business development, financial condition and results of operations.

The “ Risk Factors ” section of this prospectus, any accompanying prospectus supplement, and our annual reports on Form 20-F and reports on Form 6-K filed with the SEC and incorporated by reference into this prospectus discusses the principal contingencies and uncertainties to which we believe we are subject, which should be considered in evaluating any forward-looking statements contained or incorporated by reference in this prospectus or in any prospectus supplement.

<div align='center'>10</div>

TABLE OF CONTENTS

### RISK FACTORS
Investing in our securities involves risks. Before making an investment decision, you should carefully consider the risks described under “ Risk Factors ” in the applicable prospectus supplement and in our most recent annual report on Form 20-F, and in our updates, if any, to those risk factors in our reports on Form 6-K incorporated by reference into this prospectus, together with all of the other information appearing in this prospectus or incorporated by reference into this prospectus and any applicable prospectus supplement, in light of your particular investment objectives and financial circumstances. In addition to those risk factors, there may be additional risks and uncertainties of which management is not aware or focused on or that management deems immaterial. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment.

<div align='center'>11</div>

TABLE OF CONTENTS

### USE OF PROCEEDS
Our management will have broad discretion over the use of the net proceeds from the sale of our securities pursuant to this prospectus, both in terms of the purposes for which they will be used and the amounts that will be allocated for each purpose. Unless otherwise indicated in the applicable prospectus supplement or in any free writing prospectus that we may authorized to be provided to you in connection with a specific offering, we intend to use any net proceeds from the sale of securities under this prospectus to fund activities relating to the continued research and clinical development, manufacture or commercialization of our Tinlarebant and